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Condensation 
Prophylactic use of aspirin in women at high-risk of preeclampsia reduces 
substantially the length of stay in the neonatal intensive care unit. 
 
Short version of article title 
Secondary analysis of ASPRE trial  
 
Implications and Contributions  
A. The study was conducted in women at high-risk of preeclampsia to examine 
the effect of prophylactic use of aspirin during pregnancy on length of stay in the 
neonatal intensive care unit. 
B. Prophylactic use of aspirin reduces the length of stay in neonatal intensive care 
unit by about 70%, mainly due to a decrease in the rate of births at <32 weeks’ 
gestation because of prevention of early-preeclampsia. 
C. In women at high-risk of preeclampsia prophylactic use of aspirin reduces 
substantially both the risk of preterm-preeclampsia and length of stay in neonatal 
intensive care unit. 
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ABSTRACT 
Background: Preeclampsia is a major pregnancy complication with adverse short- 
and long-term implications for both the mother and baby. Screening for 
preeclampsia at 11-13 weeks’ gestation by a combination of maternal 
demographic characteristics and medical history with measurements of 
biomarkers can identify about 75% of women that develop preterm-preeclampsia 
with delivery at <37 weeks’ gestation and 90% of those with early-preeclampsia at 
<32 weeks, at a screen positive rate of 10%. A recent trial (Combined Multimarker 
Screening and Randomized Patient Treatment with Aspirin for Evidence-Based 
Preeclampsia Prevention) has reported that in women identified by first-trimester 
screening as being at high-risk for preeclampsia, use of aspirin (150 mg/day from 
the first to the third trimester), compared to placebo, reduced the incidence of 
preterm-preeclampsia, which was the primary outcome, by 62% (95% confidence 
interval, 26-80%) and the incidence of early-preeclampsia by 89% (95% 
confidence interval, 53-97%). The surprising finding of the trial was that despite the 
reduction in preeclampsia the incidence of admission to the neonatal intensive 
care unit, which was one of the secondary outcomes, was not significantly 
affected (odds ratio 0.93, 95% confidence interval, 0.62-1.40). 
Objective: To examine the effect of prophylactic use of aspirin during pregnancy in 
women at high-risk of preeclampsia on length of stay in the neonatal intensive 
care unit. 
Study design: This was a secondary analysis of data from the Aspirin for 
Evidence-Based Preeclampsia Prevention trial to assess evidence of differences 
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in the effect of aspirin on length of stay in neonatal intensive care. Bootstrapping 
was used for the comparison of mean length of stay between the aspirin and 
placebo groups. Logistic-regression was used to assess treatment effects on stay 
in the neonatal intensive care unit.  
Results: In the trial there were 1620 participants and 1571 neonates were 
liveborn. The total length of stay in neonatal intensive care was substantially 
longer in the placebo than aspirin group (1696 vs. 531 days). This is a reflection of 
significantly shorter mean lengths of stay in babies admitted to the neonatal 
intensive care unit from the aspirin than the placebo group (11.1 vs. 31.4 days; a 
reduction of 20.3 days (95% confidence interval, 7.0-38.6; p=0.008). Neonatal 
intensive care of babies born at <32 weeks’ gestation contributed 1856 (83.3%) of 
the total of 2227 days in intensive care across both treatment arms. These 
occurred in 9 (1.2%) of the 777 livebirths in the aspirin group and in 23 (2.9%) of 
794 in the placebo group (odds ratio 0.42; 95% confidence interval, 0.19-0.93; 
p=0.033). Overall, in the whole population, including zero lengths of stay for those 
that were not admitted to the neonatal intensive care unit, the mean length of stay 
was longer in the placebo than aspirin group (2.06 vs 0.66 days; reduction of 1.4 
days (95% confidence interval, 0.45-2.81; p=0.014). This corresponds to a 
reduction in length of stay of 68% (95% confidence interval, 20-86%). 
 
Conclusions: In pregnancies at high-risk of preeclampsia administration of aspirin 
reduces the length of stay in the neonatal intensive care unit by about 70%. This 
reduction could essentially be attributed to a decrease in the rate of births at <32 
weeks’ gestation, mainly because of prevention of early preeclampsia. The 
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findings have implications for both short- and long-term healthcare costs as well 
as infant survival and handicap. 
 
 
Key words: First trimester screening, Aspirin, ASPRE trial, Preeclampsia, 
Neonatal intensive care, Health economics. 
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INTRODUCTION 
 
Preeclampsia (PE), which affects 2-3% of pregnancies, is a major cause of death 
and morbidity for the mother and perinatal death and long-term handicap for the 
baby.1-10 Additionally, the condition has important implications on healthcare 
cost;11 in the USA it was estimated that in 2012 the cost of PE within the first 12 
months of delivery was $2.18 billion and was disproportionately borne by births of 
low gestational age.12 
 
In the last decade extensive research has led to the development of a method of 
first-trimester screening for PE.13-16 A combination of maternal demographic 
characteristics and medical history with measurements of mean arterial pressure 
(MAP), uterine artery pulsatility index (UTPI) and serum placental growth factor 
(PLGF) at 11-13 weeks’ gestation can identify about 75% of women that develop 
preterm-PE with delivery at <37 weeks’ gestation and 90% of those with early-PE 
with delivery at <32 weeks, at a screen positive rate of 10%.16 Several randomized 
studies investigated the possibility of preventing PE by the prophylactic use of 
aspirin and reported contradictory results.17-20 Recent meta-analyses reported that 
aspirin reduces the risk of PE by >60%, provided the daily dose of the drug 
is >100 mg, the gestational age at onset of therapy is <16 weeks and the outcome 
measure is preterm-PE rather than total PE.19-20 A recent multicentre double-blind 
trial, Combined Multimarker Screening and Randomized Patient Treatment with 
Aspirin for Evidence-Based Preeclampsia Prevention (ASPRE trial) has reported 
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that in women with singleton pregnancies identified by the first-trimester combined 
test as being at high-risk for PE, aspirin (150 mg/day) vs. placebo from 11 to 14 
until 36 weeks’ gestation was associated with a 62% reduction in the incidence of 
preterm-PE, which was the primary outcome (odds ratio 0.38; 95% confidence 
limits [CI], 0.20-0.74), and 89% reduction in early-PE (odds ratio 0.11, 95% CI 
0.03-0.47).21 The surprising finding of the ASPRE trial was that despite the 
reduction in preterm-PE and early-PE the incidence of admission to the neonatal 
intensive care unit (NICU), which was one of the secondary outcomes, was not 
significantly affected (odds ratio 0.93; 95% CI, 0.62-1.40). 
 
The objective of this study, which is a secondary analysis of data from the ASPRE 
trial, is first, to examine the effect of aspirin on length of stay in NICU and evaluate 
the potential impact on health care cost of screening for PE and treatment of the 
high-risk group by aspirin. 
 
METHODS 
 
Study design and population 
 
The ASPRE trial was conducted at 13 maternity hospitals in the United Kingdom, 
Spain, Italy, Belgium, Greece, and Israel.21 In the 13 participating hospitals routine 
screening for preterm-PE was carried out at 11-13 weeks’ gestation by an 
algorithm combining maternal demographic characteristics and medical and 
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obstetrical history,15 and the measurements of MAP,22 UTPI23 and serum 
pregnancy associated plasma protein-A and PLGF (PAPP-A and PlGF 1-2-3TM 
kits, DELFIA® Xpress random access platform; PerkinElmer Inc. Wallac Oy, 
P.O.Box 10, 20101 Turku, Finland).  
 
The eligibility criteria for the trial were maternal age >18 years, no serious mental 
illness or learning difficulties, singleton pregnancy with live fetus with no major 
abnormality demonstrated on the 11-13 weeks scan and estimated risk for 
preterm-PE of >1 in 100.21 Eligible women were randomly assigned, in a 1:1 ratio, 
with the use of a web-based system to receive either aspirin or placebo and in the 
random-sequence generation there was stratification according to participating 
center. After randomization, study participants were prescribed the investigational 
medicinal product, received instructions to take one tablet every night throughout 
the study and to stop taking tablets at 36 weeks’ gestation or in the event of early 
delivery, at the onset of labor.   
 
The primary outcome measure was delivery with PE at <37 weeks’ gestation. 
Preeclampsia was defined as per the International Society for the Study of 
Hypertension in Pregnancy.24 Secondary outcomes were: adverse outcomes of 
pregnancy <34, <37 and ≥37 weeks’ gestation, stillbirth or neonatal death, 
neonatal morbidity, neonatal therapy, and low birth weight.  
 
Quality control of screening and verification of adherence to protocol were 
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performed by the University College London Comprehensive Clinical Trials Unit 
(UCL-CCTU). Approval for the trial was obtained from the relevant research ethics 
committee and competent authority in each country in which the trial was 
conducted.  
 
Statistical analyses 
 
Statistical analyses were performed on an intention-to-treat basis. The main 
analysis focuses on the assessment of the treatment effect on mean length of 
stay in NICU with zero values for babies who did not enter the unit. The rationale 
for this is that the expected total length of stay in a population is given by the 
population size multiplied by the mean length of stay. The data on length of stay 
contained very large numbers of zeros and the sample means were dominated by 
a relatively small number of babies with long lengths of stay. Rather than relying 
on the central limit theorem for inference, we therefore chose to use bootstrapping. 
The results presented were obtained from 100,000 bootstrap samples. We 
conducted the following additional analyses to examine the sensitivity of our 
conclusions: first, we applied t-tests to the difference in mean lengths of stay and 
Fiellers ratio of means and second, we examined the effect of truncating the 
extremely long lengths of stay. The results from these analyses did not alter 
materially the inferences regarding the effect of treatment on mean length of stay 
and are presented as supplementary information [Appendix 1]. 
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Logistic-regression, with adjustment for the effect of the estimated risk of PE at 
screening and participating centers, was used to assess treatment effects on stay 
in the NICU. Separate analyses were conducted for admissions overall, for 
admissions with stays of >7, >14, >21 days and for admissions with gestational 
ages <32 and <37 weeks; overall, with PE and without PE. The treatment effect 
was quantified as odds ratio with 95% CI in the aspirin group. No corrections were 
made for multiple comparisons. 
 
The statistical software package R was used for data analyses.25 The R packages 
lme426 and boot27 were used for mixed effects logistic regression and 
bootstrapping.   
 
RESULTS  
 
In the ASPRE trial there were 822 participants in the placebo group and 798 in the 
aspirin group.21 There were no significant differences between the aspirin and 
placebo groups in baseline characteristics.21 In the placebo group, there were 16 
miscarriages or pregnancy terminations at <24 weeks’ gestation, 12 stillbirths at 
>24 weeks and 794 live births. In the aspirin group, there were 14 miscarriages or 
pregnancy terminations, 7 stillbirths, and 777 live births. 
 
Rates of admission to NICU and length of stay by treatment group are shown in 
Table 1 and Figure 1. There was no significant difference in rates of admission to 
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NICU between the aspirin and placebo groups (6.2% vs. 6.8%; odds ratio 0.94; 95% 
CI, 0.63-1.42). However, the total length of stay in NICU in the aspirin group was 
substantially shorter than in the placebo group (531 vs. 1696 days). This is a 
reflection of significantly shorter mean lengths of stay in babies admitted to NICU 
from the aspirin group than from the placebo group (11.1 days compared to 31.4 
days); a reduction of 20.3 (95% CI, 7.0-38.6) days (p=0.008). In the whole 
population, including zero values for those that were not admitted to the NICU, the 
mean length of stay was 2.06 days in the placebo group and 0.66 days in the 
aspirin group; therefore, aspirin reduced the mean length of stay by an estimated 
1.40 days (95% CI, 0.45 to 2.81 days; p=0.014). 
 
The reduction in total length of stay in NICU in the aspirin group could essentially 
be attributed to a decrease in the rate of births at <32 weeks’ gestation, mainly 
because of prevention of early-PE, and consequent decrease in number of babies 
with prolonged stays of >14 days (Table 1 and Figure 1). After 32 weeks’ 
gestation there is flattening in the cumulative length of stay in NICU for both the 
aspirin and placebo groups (Figure1).  
 
Babies born at <32 weeks’ gestation contributed to 1856 (83.3%) of the total of 
2227 days in NICU across both treatment arms; these occurred in 1.2% of 
livebirths in the aspirin group and in 2.9% in the placebo group (odds ratio 0.42; 
95% CI, 0.19-0.93). Admission to NICU occurred in all 32 babies born at <32 
weeks’ gestation, in 23 (67.6%) of 34 born at 32-34 weeks, in 13 (12.5%) of 104 
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born at 35-36 weeks and in 34 (2.4%) of the 1401 born at 37-42 weeks.  
 
Prolonged stay in NICU for >14 days contributed to 1914 (85.9%) of the total of 
2227 days across both treatment arms; these occurred in 1.0% of livebirths in the 
aspirin group and in 3.0% in the placebo group (odds ratio 0.30; 95% CI, 
0.11-0.81) and this is a reflection of the reduction in the number of babies born at 
<32 weeks’ gestation. The length of stay in NICU varied for individual babies from 
1 to 230 days; it was 1-3 days in 39 (38.2%) of the 102 babies, 4-6 days in 11 
(10.8%), >7 days in 52 (51.0%), >14 days in 32 (31.4%) and >21 in 23 (22.5%).  
 
The effect of aspirin in reducing the length of stay in NICU was partly mediated by 
a reduction in the rate of PE (Table 1). The incidence of babies admitted to the 
NICU after delivery because of PE was 2.3% (18 of 794) in the placebo group and 
0.3% (2 of 777) in the aspirin group (odds ratio 0.11; 95% CI, 0.02-0.50). In the 
pregnancies delivering at <37 and <32 weeks’ gestation the admission to NICU 
was 2.0% and 0.9%, respectively in the placebo group and 0.1% and 0% in the 
aspirin group (odds ratio 0.06; 95% CI, 0.01-0.50 and odds ratio 0.00; 95% CI, 
0.00-0.56, respectively). Aspirin also had a non-significant effect in reducing the 
length of stay in NICU in pregnancies without PE with delivery at <32 weeks’ 
gestation (odds ratio 0.59; 95% CI, 0.26-1.36). There were 16 (2.0%) babies from 
the placebo group (8 after spontaneous birth, 7 after iatrogenic birth for fetal 
growth restriction and 1 for maternal indications) and 9 (1.2%) from the aspirin 
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group (6 after spontaneous birth, 2 after iatrogenic birth for fetal growth restriction 
and 1 for maternal indications). 
 
Impact on cost 
 
In a population of 10,000 pregnancies undergoing first-trimester screening for PE, 
at a screen positive rate of 10%, 1,000 pregnancies would be classified as 
high-risk. If these 1,000 pregnancies had not received aspirin and the mean 
length of stay in NICU was 2.06 days, the expected total length of stay would be 
2,060 days. If they had received aspirin the expected total length of stay would be 
660 days.  It is difficult to attach specific costs to daily lengths of stay but, if we 
assume $4,000, then the cost saving from such care by a policy of screening 
10,000 pregnancies and treating the high-risk group with aspirin would be $4,000 
x (2,060 – 660) = $5.6m. This is equivalent to $560 per patient screened, which is 
well in excess of the cost of screening. 
 
COMMENT 
 
Principal findings of this study 
 
The ASPRE trial demonstrated that, in women with singleton pregnancies 
identified by means of first trimester screening as being at high-risk for PE, the 
prophylactic use of aspirin reduces the incidence of preterm-PE and early-PE by 
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approximately 60% and 90%, respectively.21 This secondary analysis 
demonstrated that use of aspirin reduces the length of stay in NICU by 
approximately 70%. This reduction could essentially be attributed to a decrease in 
the rate of births at <32 weeks’ gestation, mainly because of prevention of 
early-PE. 
 
The consequence of reduction in length of stay in NICU is substantial saving in 
healthcare cost which is well in excess of the cost of population screening and 
treatment of the high-risk group with aspirin. The study provides the basis for 
formal health economic studies. 
 
Strengths and limitations of this study  
 
ASPRE was a large multicentre trial that was powered for the primary outcome of 
preterm-PE and the statistical power for detecting less frequent outcomes is 
inevitably poor. This secondary analysis was triggered by the apparent 
contradiction that although aspirin use was associated with a major reduction in 
preterm- and early-PE there was no evidence of reduction in NICU admission. In 
this respect, the findings that first, babies born at <32 weeks’ gestation 
contributed >80% of total length of stay in NICU, second, the incidence of birth at 
<32 weeks was lower in the aspirin group and third, in the aspirin group the total 
length of stay in NICU was substantially reduced, are not surprising.  
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However, it has to be recognised that this is an unplanned secondary analysis 
and, because of the small number babies with longer lengths of stay, there is 
considerable uncertainty in the estimation of the difference in mean length of stay 
between the aspirin and placebo groups. Including zero lengths of stay for those 
not admitted to the NICU, the 95% CI for the difference in mean length of stay 
ranged from 0.45 to 2.81 days. In a screened population of 10,000 pregnancies, 
treating 10% screened positive, this CI translates into an interval from 450 to 
2,810 days. Assuming a cost of $4,000 per day, the corresponding intervals for 
the cost saving would range from $1.8m to $11.2m which equate to between $180 
and $1,120 per screening test.   
 
Prediction and prevention of PE 
 
The traditional approach of identifying women at high-risk of PE that could 
potentially benefit from the prophylactic use of aspirin is based on maternal 
characteristics and features of the medical and obstetrical histories.28,29 However, 
the performance of such screening is poor. With the method recommended by the 
National Institute for Health and Clinical Excellence (NICE) in the UK the detection 
rate of preterm-PE is about 40% at screen positive rate of 10% and with the 
method recommended by the American College of Obstetricians and 
Gynecologists in the USA the detection rate is 90% but at a screen positive rate of 
67%.28-31 
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Our approach to screening is to use Bayes’ theorem to combine information from 
maternal factors with biophysical and biochemical measurements obtained at 
11-13 weeks’ gestation to derive the patient-specific risk. The method, which 
detects around 75% of cases of preterm-PE at FPR of 10%, was originally 
developed from a study of 58,884 pregnancies,13,14 updated with data from 
prospective screening in 35,948 pregnancies,15,16 and subsequently validated in 
two independent datasets derived from multicenter studies in 8,775 and 25,797 
pregnancies, respectively.32,33 
 
Prophylactic use of aspirin was previously thought to reduce the risk of PE by only 
10%.17 However, recent evidence suggests that the target for first-trimester 
screening should be severe PE leading to preterm birth, rather than all PE. In 
ASPRE, use of aspirin was associated with a 62% reduction in the rate of 
preterm-PE with no significant effect on rate of term-PE; a secondary analysis of 
the trial reported that the reduction of preterm-PE was even greater (75%) if the 
compliance was >90%.21,34 A recent systematic review and meta-analysis of 16 
trials in a combined total of 18,907 participants, reported that aspirin (at a daily 
dose of >100 mg and gestational age at onset of therapy of <16 weeks) reduces 
the risk of preterm-PE by 67%; there was no significant benefit if the dose was 
<100 mg/day and the onset of therapy was >16 weeks.20 
 
Implications of prevention of early preterm birth 
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This secondary analysis of the ASPRE trial demonstrated that use of aspirin 
reduces the rate of early preterm birth and the potential consequence in 
healthcare cost from neonatal intensive care. In the ASPRE trial there was no long 
term follow up of the neonates. However, reduction in the risk of birth at <32 
weeks’ gestation is likely to be associated with reduction in risk of infant death, 
cerebral palsy and long term use of specialized health-care resources.  
 
A study of 5567 neonates born alive at 22-34 weeks’ gestation in 2011 in France, 
reported that at 2-years of age survival without neuromotor or sensory disabilities 
was 97.5% for those born at 32-34 weeks decreasing to 81.2% in those born at 
22-31 weeks.35 Similarly, a study of 2901 livebirths at 22-32 completed weeks’ 
gestation in 1997 in France, reported that at 5-years of age 14% of the children 
had moderate to severe disability and 25% had minor disability. Specialized 
health-care resources were used by 34% of the children born prematurely, 
compared with only 16% in a reference group of children born at 39-40 weeks.36  
 
A study in Norway reported follow-up from birth to adulthood in 867,692 
individuals who were born alive and without congenital anomalies between 1967 
and 1983.37 The rate of death within the first 5 years of life was 80% for those born 
at 23-27 weeks’ gestation and this decreased to 40% for births at 28-30 weeks, 
11.2% for births at 31-33 weeks, 2.3% for births at 34-36 and 0.6% for births at 
≥37 weeks. In the survivors, the respective rates of cerebral palsy were 9.1%, 
6.0%, 1.9%, 0.3% and 0.1%, the rates of mental retardation were 4.4%, 1.8%, 
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1.0%, 0.7% and 0.4% and the rates of medical disability severely affecting work 
capacity were 10.6%, 8.2%, 4.2%, 2.4% and 1.7%. 
 
Conclusion  
 
In pregnancies at high risk of PE identified by screening at 11-13 weeks’ gestation 
administration of aspirin reduces the rate of birth at <32 weeks’ gestation and 
length of stay in NICU. The findings have implications for both short- and 
long-term healthcare costs as well as infant survival and handicap. 
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Figure legends 
Figure 1. Cumulative number babies admitted to the neonatal intensive care unit 
(NICU) according to gestational age at birth for the placebo (blue circles) and 
aspirin group (red circles). In the left panel is the cumulative number of all babies 
admitted to NICU, in the centre panel is the cumulative length of stay in NICU and 
in the right panel is the cumulative number of babies with intensive care for >14 
days.  
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Table 1. Admission to neonatal intensive care unit in livebirths from the aspirin and 
placebo groups according to length of stay and gestational age at birth.  
 
 
*These estimates relate to the population of livebirths as distinct from the previous publication 21 
where study population comprised all pregnancies.   
 
 
 
Outcome measure Aspirin Placebo 
 
   
Length of stay in NICU (d) 
  
Differences in means (95% CI) 
Study population: admissions to NICU n=48 n=54  
Mean (standard deviation) 11.1 (23.4) 31.4 (53.0) 20.3 (7.0 – 38.6) 
Study population: all cases in the trial n=798 n=822  
Mean (standard deviation) 0.66 (6.3) 2.06 (15.5) 1.40 (0.45 - 2.81) 
    
Number of babies in NICU 
  
Odds Ratio (95% CI) 
Study population: livebirths* n=777 n=794  
Number by gestational age at birth    
  Any, n (%) 48 (6.2) 54 (6.8) 0.94 (0.63 - 1.42) 
     Preeclampsia 2 (0.3) 18 (2.3) 0.11 (0.02 - 0.50) 
     No preeclampsia  46 (5.9) 36 (4.5) 1.38 (0.88 – 2.15) 
  <37 w, n (%) 28 (3.6) 40 (5.0) 0.75 (0.54 - 1.04) 
     Preeclampsia 1 (0.1) 16 (2.0) 0.06 (0.01 - 0.50) 
     No preeclampsia  27 (3.5) 24 (3.0) 0.96 (0.66 - 1.38) 
     - Spontaneous  17 (2.2) 14 (1.8) 1.27 (0.62 - 2.60) 
     - Medically indicated 10 (1.3) 10 (1.3) 1.01 (0.38 - 2.73) 
  <32 w, n (%) 9 (1.2) 23 (2.9) 0.42 (0.19 - 0.93) 
     Preeclampsia 0 7 (0.9) 0.00 (0.00 - 0.56) 
     No preeclampsia  9 (1.2) 16 (2.0) 0.59 (0.26 - 1.36) 
     - Spontaneous  6 (0.8) 8 (1.0) 0.79 (0.27 - 2.28) 
     - Medically indicated 3 (0.4) 8 (1.0) 0.41 (0.11 - 1.54) 
Number by length of stay    
  ≥ 7 days, n (%) 18 (2.3) 34 (4.3) 0.57 (0.32 - 1.04) 
  ≥ 14 days, n (%) 8 (1.0) 24 (3.0) 0.36 (0.16 - 0.83) 
  ≥ 21 days, n (%) 5 (0.6) 18 (2.3) 0.30 (0.11 - 0.81) 
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Appendix 1: Supplementary Information 
 
In evaluation of interventions applied to large populations, by virtue of the central limit 
theorem, totals can be assumed to follow a Gaussian distribution regardless of the 
distribution of individual observations. The mean of the distribution of the total is Nµ where N 
is the population size and µ the mean of the distribution for individuals. This relationship 
between the mean of the total and the mean of the individuals does not apply to other 
measures of location such as the median. In this context, the mean of the distribution is 
therefore an appropriate measure of location, even in situations where it would not be 
considered as appropriate as a measure of central tendency for the distribution of 
individuals, as might be the case for a highly skewed distribution.   
 
In this paper we focus on the effect of aspirin on mean length of stay (LOS) in the Neonatal 
Intensive Care Unit.  These data have a very highly skewed distribution as do most data on 
LOS. A technique whose validity does not depend on any specific form of underlying 
distribution is the bootstrap. However, even with bootstrapping there are concerns that 
extremes will impact on the inferences concerning means. See O'Hagan A, Stevens JW. 
Assessing and comparing costs: how robust are the bootstrap and methods based on 
asymptotic normality? Health Econ 2003;12:33-49.  
 
In the Table below we present the results of a sensitivity analysis looking at the effect of 
truncating extremely large lengths of stay.  We compare the results of bootstrapping with 
those obtained from applying t-tests that rely on the central limit theorem. Further support for 
the robustness of our conclusion regarding the effect of aspirin on LOS is provided by the 
effect of aspirin on the number of stays for ≥7, ≥14 and ≥21 days given in Table 1 of the 
paper.   
 
Estimates and 95% confidence intervals for differences in mean length of satay (LOS) 
Truncation  Difference in mean LOS (P-A) Ratio of mean LOS (A/P) 
None  Bootstrap 1.40 (0.54 to 2.81) 0.32 (0.14 to 0.80) 
  t test 1.40 (0.25 to 2.55) 0.32 (0.10 to 0.77) 
180 days Bootstrap 1.30 (0.45 to 2.83) 0.34 (0.15 to 0.83) 
 
t test 1.30 (0.23 to 2.37) 0.34 (0.11 to 0.79) 
90 days Bootstrap 0.90 (0.27 to 1.68) 0.40 (0.20 to 0.83) 
  t test 0.90 (0.20 to 1.60) 0.40 (0.17 to 0.79) 
 
Bootstrapping 
Bootstrap confidence intervals results were obtained using the bootstrap with a log 
transformation for the ratio of mean LOS.  100,000 replicates were used as shown in the 
Figure below. Results were obtained using the package boot in R. The intervals are BCa 
intervals. Angelo Canty and Brian Ripley (2017). boot: Bootstrap R (S-Plus) Functions. R 
package version 1.3-20. 
t-test 
Confidence intervals for ratios of means were obtained from Fieller’s theorem implemented 
using the mratios package in R. Gemechis Dilba Djira, Mario Hasler, Daniel Gerhard and 
Frank Schaarschmidt (2012). mratios:  Inferences for ratios of coefficients in the general 
linear model. R package version 1.3.17.  https://CRAN.R-project.org/package=mratios. 
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